Details of how to report adverse events are available at the bottom of the page.
For full information on a Roche medicine, please see the relevant Summary of Product Characteristics.
† Figures taken from data reported from April 2021 - March 2022.
Optimising SACT Delivery: Case Studies in Tecentriq SC Adoption
Explore the case studies below to discover how subcutaneous Tecentriq SC is being implemented across various NHS settings. Learn how different Trusts – from large teaching hospitals to community-based centers – are addressing capacity challenges, streamlining workflows, and enhancing patient experience. Find the insights most relevant to your specific service model and discover the potential for positive change.
Review six case studies decentralising the delivery of SACT with subcutaneous Tecentriq, addressing service challenges, opportunities, and exploring potential future pathways for SACT administration
Teaching Hospital in Southeast England Boosts Capacity by Shifting Patients to Subcutaneous Tecentriq Administration in Outpatient Unit - Barking, Havering and Redbridge University Hospitals NHS Trust (Page 5).
Haematology and Oncology Center in South West England Introduces Subcutaneous Tecentriq for Single-Agent Treatment - University Hospitals Bristol and Weston NHS Foundation Trust (Page 6).
Community Cancer Nursing Team in East of England Delivers Subcutaneous Tecentriq at Home to Reduce Patient Travel - North West Anglia NHS Foundation Trust (Page 8).
South West England Trust Eases Day Unit Load by Switching to Subcutaneous Formulation of Tecentriq - Torbay and South Devon NHS Foundation Trust (Page 10).
East Midlands NHS Trust Tackles Capacity Issues with Subcutaneous Tecentriq and New Patient Process Enhancements - University Hospitals of Leicester NHS Trust (Page 11).
East Yorkshire Hospital Alleviates Capacity Strain by Establishing Supportive Treatment Unit and Transitioning to Subcutaneous Tecentriq - Hull University Teaching Hospitals NHS Trust (Page 12).
Identify best practices for stakeholder engagement and project planning to support implementation
Read how a cancer centre has recognised advantages of implementing a switch to a SC formulation, and how they have planned and operationalised changes to their services.
Click on the relevant region below to contact your local disease level partner (DLP) or clinical nurse educator (CNE).
Tecentriq as monotherapy is indicated as adjuvant treatment following complete resection and platinum-based chemotherapy for adult patients with NSCLC with a high risk of recurrence whose tumours have PD-L1 expression on ≥ 50% of tumour cells (TC) and who do not have EGFR mutant or ALK-positive NSCLC.
Tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous NSCLC. In patients with EGFR mutant or ALK-positive NSCLC, Tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies.
Tecentriq, in combination with nab-paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous NSCLC who do not have EGFR mutant or ALK-positive NSCLC.
Tecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic NSCLC whose tumours have a PD-L1 expression ≥ 50% TC or ≥ 10% tumour-infiltrating immune cells (IC) and who do not have EGFR mutant or ALK-positive NSCLC.
Tecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic NSCLC after prior chemotherapy. Patients with EGFR mutant or ALK-positive NSCLC should also have received targeted therapies before receiving Tecentriq.
Tecentriq as monotherapy is indicated for the 1L treatment of adult patients with advanced NSCLC who are
ineligible for platinum-based therapy (platinum ineligible criteria can be found in section 5.1 of the SPC)
Tecentriq, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).
Abbreviations:
ALK, anaplastic lymphoma kinase; EGFR, epidermal growth factor receptor; IC, immune cell; IV, intravenous; LCEF, Lung Cancer Expert Forum; NSCLC, non small cell lung cancer; PD L1, programmed death ligand 1; SC, subcutaneous
References:
- The Royal College of Radiologists. The SACT capacity crisis in the NHS. Available at: https://www.rcr.ac.uk/media/updj5x5h/rcr-policy_policy-briefing-the-sact-capacity-crisis-in-the-nhs.pdf. Accessed25 June 2025
- Royal College of Radiologists. (2024). Unpacking the Darzi review: Five key takeaways for diagnostic and cancer services in the NHS. Available at https://www.rcr.ac.uk/news-policy/latest-updates/unpacking-the-darzi-review-five-key-takeaways-for-diagnostic-and-cancer-services-in-the-nhs. Accessed July 2025
- Tecentriq SC SmPC
- Tecentriq IV SmPC